Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review provides a comprehensive overview of the mechanisms, efficacy, and adverse reactions of drugs commonly used for treating benign prostatic hyperplasia but reports no new clinical results.

This review discusses recent advancements and new approvals in the medical treatment of lower urinary tract symptoms, particularly highlighting drugs for nocturia and ongoing trials for multiple related conditions, while reporting no new clinical results.

This review discusses the efficacy of the lipidosterolic extract of Serenoa repens for treating lower urinary tract symptoms and reports no new clinical results; the authors propose further examination of the existing literature and guidelines.

In this case study, a 36-year-old female with severe lupus enteritis and intestinal pseudo-obstruction showed significant clinical improvement after treatment with intravenous methylprednisolone, hydroxychloroquine, and cyclophosphamide, highlighting the complexities and challenges in diagnosing and managing atypical lupus manifestations.

This article reviews the management of lower urinary tract symptoms, highlighting drug therapy advancements that have reduced the frequency of surgical interventions.

This randomized, placebo-controlled trial reported that USPlus PRO saw palmetto extract significantly improved lower urinary tract symptoms, including voiding, incomplete emptying, and weak stream, as well as sexual function in males over 12 weeks, while maintaining a favorable safety profile.

This review examines the cognitive effects of medications for lower urinary tract symptoms and indicates that muscarinic antagonists, particularly oral oxybutynin, pose the highest risk for cognitive impairment.

Men's age, urinary symptoms, and heart health risks create different types of erectile dysfunction.

This review discusses medical treatments for lower urinary tract symptoms suggestive of benign prostatic hyperplasia, focusing on their effects, side-effects, and implications for treatment goals, but reports no new clinical results.

This case report describes a young female with pediatric SLE and latent TB who was found to have gastrointestinal tuberculosis, a rarely recognized and often misdiagnosed condition, highlighting the diagnostic challenges and need for early recognition in such cases.

This study found that after 12 weeks of taking the trial product SHPro®, participants reported improvements in prostate symptom scores and erectile function, with confirmed safety.

In this study, men with benign prostatic hyperplasia who took finasteride for four years experienced reduced urinary symptoms, fewer surgeries, less acute urinary retention, increased urinary flow rates, and decreased prostate volume.

This study found that patients with bladder outlet obstruction and moderately enlarged prostates are likely to successfully discontinue the a-blocker doxazosin after 9 months of combination therapy with finasteride.

This review concludes that global literature supports the lipidosterolic extract of Serenoa repens as efficacious and safe for treating lower urinary tract symptoms, with some studies showing equivalence to common pharmacologic agents.

The authors concluded that components of metabolic syndrome were strongly associated with severe lower urinary tract symptoms in Latin American men, while alopecia was not an independent predictor.

This study found that finasteride alone is highly effective in preventing Candida albicans urinary biofilms and shows synergistic activity with fluconazole in vitro, suggesting potential for further clinical investigation.

This study found that red ginseng oil (RXGIN) significantly improved lower urinary tract symptoms and some aspects of sexual function in men, with no serious adverse events reported.

This study in male rats found that Cernitin™ significantly relieved pain and decreased prostate weight in models of chronic prostatitis and benign prostatic hyperplasia, suggesting an anti-inflammatory effect.

This review examines the use of tadalafil and finasteride as a combined therapy for BPH, suggesting it may effectively reduce treatment-related sexual adverse events and improve symptom relief.

This article discusses androgenetic alopecia as a potential early marker for benign prostatic hyperplasia but reports no new clinical findings.

This study found that men aged 60 or older with postoperative urinary retention were more likely to undergo bladder outlet procedures within three years.

This study reports on biofeedback treatment for dysfunctional voiding in three adult cases, providing insights into this condition when diagnosed beyond childhood.

This study reports that saw palmetto may effectively treat benign prostatic hyperplasia symptoms and potentially stimulate hair growth with generally mild side effects.

This study found that patients with androgenetic alopecia frequently had higher PSA levels and more significant urinary symptoms, likely due to older age, though prostate weight did not differ.

This review discusses various treatment options for lower urinary tract symptoms in men, including behavioral, pharmacologic, and surgical interventions, and reports no new clinical results; the authors emphasize first-line therapy with behavioral and pharmacologic approaches.

This editorial discusses the management of lower urinary tract symptoms in elderly males and does not provide new research findings.

This case report describes a 66-year-old male with benign prostatic hyperplasia who developed urinary incontinence after starting venlafaxine, which resolved upon discontinuation of the medication.

Human prostate cells produce more WISP1/CCN4 when there's not enough oxygen.

This paper discusses risk factors and prevention strategies for acute urinary retention secondary to benign prostatic hyperplasia, emphasizing the role of PSA levels and the benefits of medications like finasteride and alpha-blockers, but reports no new clinical results.

This review discusses the stratification and management of male patients with lower urinary tract symptoms and benign prostatic hyperplasia in primary care and reports no new clinical results.